Enliven Therapeutics, Inc. (ELVN) · Nov 5, 2026 · Earnings
Beat — $0.36 loss per share vs ~$0.45 consensus
Enliven’s quarterly earnings beat expectations while relcobatinib stays on track for its first pivotal Phase 3 trial before year-end.
Enliven is a cash-rich clinical-stage biotech moving relcobatinib from Phase 1 into its first pivotal Phase 3 trial for previously treated chronic myeloid leukemia. The company had already announced FDA alignment on the ENABLE-2 design on October 6, 2026, so the quarter’s central development milestone was largely known before this filing.
The earnings were modestly ahead of the available benchmark. Enliven reported a third-quarter loss of $0.36 per share versus published expectations of roughly $0.45, making this a beat rather than a miss. The underlying business is still pre-revenue and loss-making, however, with net loss widening year over year as the company advances its clinical program.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Net loss per share (Statements of Operations) | $0.36 loss | $0.32 loss | $0.45 loss |
| R&D expense (Financial Results) | $28.0M | $18.2M | |
| G&A expense (Financial Results) | $8.0M | $6.9M | |
| Net loss (Statements of Operations) | $27.7M | $20.1M | |
| Cash, equivalents and marketable securities (Balance Sheets) | $884.4M | $462.6M at Dec. 31, 2025 |
The operational story is advancing, but this filing mostly confirms rather than changes it. Enliven reiterated that it has FDA agreement on the final ENABLE-2 design and expects to begin the approximately 450-patient randomized trial before the end of 2026. 〔0〕 〔1〕 That removes a major design uncertainty, but because the FDA alignment was disclosed a month earlier, the filing adds execution confirmation more than a fresh catalyst.
Funding is no longer the immediate constraint. Enliven ended September with $884.4 million in cash, cash equivalents and marketable securities and says that supports operations into 2030. That gives the company room to run ENABLE-2 without an obvious near-term financing overhang, although spending is rising as development moves into a pivotal trial.
Bottom line: This is a modestly constructive quarter: the loss beat expectations and Enliven remains funded and on schedule for Phase 3. The important regulatory milestone was already known, so the filing strengthens execution confidence without rewriting the story.
ENABLE-2 initiation before year-end 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!